Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nexium DTC Ads Criticized By CMS’ Scully During Medicaid Hearing

Executive Summary

Direct-to-consumer advertising for follow-on drugs such as AstraZeneca's Nexium are part of the reason for "huge" Medicaid spending on prescription drugs, Centers for Medicare & Medicaid Services Administrator Thomas Scully told a House Energy & Commerce/Health Subcommittee hearing Oct. 8

You may also be interested in...



Medicare Rx Benefit Will Be Implemented By New CMS Team; Scully Resigns

The Medicare prescription drug benefit will be implemented by a new team at the Centers for Medicare & Medicaid Services following the Dec. 16 departure of CMS Administrator Tom Scully

Medicare Rx Benefit Will Be Implemented By New CMS Team; Scully Resigns

The Medicare prescription drug benefit will be implemented by a new team at the Centers for Medicare & Medicaid Services following the Dec. 16 departure of CMS Administrator Tom Scully

Medicare Rx Benefit Costs Will Exceed $400 Bil. – Rep. Waxman

Medicare drug benefit legislation will ultimately cost well over the $400 bil. budget target, Rep. Henry Waxman (D-Calif.) predicted Oct. 29

Related Content

UsernamePublicRestriction

Register

PS042620

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel